New Age Alpha Advisors LLC Purchases New Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

New Age Alpha Advisors LLC acquired a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 16,023 shares of the company’s stock, valued at approximately $190,000.

Several other institutional investors and hedge funds also recently bought and sold shares of ROIV. GAMMA Investing LLC boosted its holdings in shares of Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock valued at $84,000 after buying an additional 1,507 shares during the period. Quarry LP grew its holdings in shares of Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after acquiring an additional 2,500 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Roivant Sciences by 550.1% in the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock worth $91,000 after acquiring an additional 6,667 shares during the last quarter. Finally, HighTower Advisors LLC acquired a new stake in Roivant Sciences during the fourth quarter valued at $121,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Buying and Selling

In other Roivant Sciences news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was bought at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the acquisition, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the completion of the sale, the chief operating officer now owns 732,294 shares in the company, valued at approximately $8,260,276.32. The trade was a 12.01 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,395,541 shares of company stock valued at $15,028,538. Insiders own 7.90% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on ROIV shares. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $17.10.

Roivant Sciences Stock Performance

ROIV opened at $10.08 on Thursday. Roivant Sciences Ltd. has a twelve month low of $9.76 and a twelve month high of $13.06. The business has a 50 day moving average price of $10.67 and a 200 day moving average price of $11.36. The firm has a market cap of $7.19 billion, a P/E ratio of -67.20 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.